The phase II Atezo-Brain trial, a single-arm study, evaluated the combination of atezolizumab, carboplatin, and pemetrexed in patients with advanced non-squamous NSCLC without EGFR/ALK alterations and with untreated, asymptomatic BMs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.